Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2015-06-02

Clinical Trial Update: A Study of RO4917838 in Patients With Sub-optimally Controlled Symptoms of Schizophrenia (NN25307) [Phase 3]

View source ↗

Summary

Phase 3 trial of RO4917838 in schizophrenia has completed; the update notes the study status but does not provide results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • RO4917838

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Schizophrenia | Phase 3 | Status: COMPLETED